Body fat content and testosterone pharmacokinetics determine gonadotropin suppression after intramuscular injections of testosterone preparations in normal men

Journal of Andrology

Volumn 30, Issue 5, 2009, Pages 602-613

  Kornmann, Britta ^a   Nieschlag, Eberhard ^a   Zitzmann, Michael ^a   Gromoll, Jörg ^a   Simoni, Manuela ^a   Von Eckardstein, Sigrid ^a,b  

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b NONE   (Switzerland)

Author keywords

Body weight; Negative feedback

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE;

ADULT; ARTICLE; BODY FAT; BODY WEIGHT; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFECT; FAT CONTENT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADIPOSE TISSUE; ADOLESCENT; ADULT; DEPRESSION, CHEMICAL; FOLLICLE STIMULATING HORMONE; GONADOTROPINS; HUMANS; LUTEINIZING HORMONE; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 66749170396     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.006296     Document Type: Article

References (38)

1. Anderson RA, Wu FC. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab. 1996;81:896-901. (Pubitemid 126423241)
2. Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999;140:414-419. (Pubitemid 29254007)
3. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab. 1995;80:2394-2403.
4. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, Nieschlag S, eds. Testosterone: Action, Deficiency, Substitution. 3rd ed. Cambridge, United Kingdom: Cambridge University Press; 2004;405-444.
5. Coviello AD, Lakshman K, Mazer NA, Bhasin S. Differences in the apparent metabolic clearance rate of testosterone in young and older men with gonadotropin suppression receiving graded doses of testosterone. J Clin Endocrinol Metab. 2006;91:4669-4675. (Pubitemid 44833455)
6. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat percent relationship. Obes Rev. 2002;3:141-146. (Pubitemid 34815232)
7. Finkelstein JS, Whitcomb RW, O'Dea LS, Longcope C, Schoenfeld DA, Crowley WF Jr. Sex steroid control of gonadotropin secretion in the human male. I. Effects of testosterone administration in normal and gonadotropin-releasing hormone-deficient men. J Clin Endocrinol Metab. 1991;73:609-620.
8. Fragoso MC, Kohek MB, Martin RM, Latronico AC, Lucon AM, Zerbini MC, Longui CA, Mendonca BB, Domenice S. An inhibin B and estrogen-secreting adrenocortical carcinoma leading to selective FSH suppression. Horm Res. 2007;67:7-11. (Pubitemid 46257002)
9. Giagulli VA, Kaufman JM, Vermeulen A. Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab. 1994;79:997-1000. (Pubitemid 24342237)
10. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87:3562-3572. (Pubitemid 34879497)
11. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003;88:562-568. (Pubitemid 36207791)
12. Hammoud AO, Gibson M, Peterson CM, Hamilton BD, Carrell DT. Obesity and male reproductive potential. J Androl. 2006;27:619-626.
13. Handelsman DJ, Farley TM, Peregoudov A, Waites GM. Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril. 1995;63:125-133.
14. Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes. 2004;53(suppl 1):S143-S151.
15. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999;84:3673-3680. (Pubitemid 30645224)
16. Jensen TK, Andersson AM, Jorgensen N, Andersen AG, Carlsen E, Petersen JH, Skakkebaek NE. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril. 2004;82:863-870. (Pubitemid 39346431)
17. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab. 2004;89:142-149. (Pubitemid 38183873)
18. Meriggiola MC, Costantino A, Cerpolini S, Bremner WJ, Huebler D, Morselli-Labate AM, Kirsch B, Bertaccini A, Pelusi C, Pelusi G. Testosterone undecanoate maintains spermatogenic suppression induced by cyproterone acetate plus testosterone undecanoate in normal men. J Clin Endocrinol Metab. 2003;88:5818-5826. (Pubitemid 38033057)
19. Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, Christensen PD, Hull L, Swerdloff RS, Wang C. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl. 2006;27:853-867. (Pubitemid 44846026)
20. Rolf C, von Eckardstein S, Koken U, Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur J Endocrinol. 2002;146:505-511. (Pubitemid 34436462)
21. Schnorr JA, Bray MJ, Veldhuis JD. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men. J Clin Endocrinol Metab. 2001;86:2600-2606.
22. Shimon I, Lubina A, Gorfine M, Ilany J. Feedback inhibition of gonadotropins by testosterone in men with hypogonadotropic hypogonadism: comparison to the intact pituitary-testicular axis in primary hypogonadism. J Androl. 2006;27:358-364. (Pubitemid 43667983)
23. Tena-Sempere M, Barreiro ML. Leptin in male reproduction: the testis paradigm. Mol Cell Endocrinol. 2002;188:9-13. (Pubitemid 34242660)
24. Veldhuis JD, Bae A, Swerdloff RS, Iranmanesh A, Wang C. Experimentally induced androgen depletion accentuates ethnicity-related contrasts in luteinizing hormone secretion in Asian and Caucasian men. J Clin Endocrinol Metab. 2005;90:1632-1638. (Pubitemid 40464030)
25. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84:3666-3672. (Pubitemid 30645223)
26. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, Moo-Young A, Sivin I, Kumar N, Small M, Sundaram K. International Committee for Contraception Research, The Population Council. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88:5232-5239.
27. von Eckardstein S, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf). 2005;7:647-655.. (Pubitemid 35316983)
28. Wang C, Berman NG, Veldhuis JD, Der T, McDonald V, Steiner B, Swerdloff RS. Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and white men - a clinical research center study. J Clin Endocrinol Metab. 1998;83:870-876. (Pubitemid 28496459)
29. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdloff RS. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab. 2004;89:2936-2941. (Pubitemid 38766388)
30. Weinbauer GF, Partsch CJ, Zitzmann M, Schlatt S, Nieschlag E. Pharmacokinetics and degree of aromatization rather than total dose of different preparations determine the effects of testosterone: a nonhuman primate study in Macaca fascicularis. J Androl. 2003;24:765-774. (Pubitemid 38133080)
31. Wenk M, Nieschlag E. Male contraception: a realistic option? Eur J Contracep Reprod Health Care. 2006;11:69-80.
32. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 1999;84:3642-3647.
33. Zitzmann M, Brune M, Kornmann B, Gromoll J, von Eckardstein S, von Eckardstein A, Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab. 2001;86:4867-4873. (Pubitemid 33020534)
34. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab. 2003b;88:2049-2054. (Pubitemid 36549876)
35. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. X-chromosome inactivation patterns and androgen receptor functionality influence phenotype and social characteristics as well as pharmacogenetics of testosterone therapy in Klinefelter patients. J Clin Endocrinol Metab. 2004;89:6208-6217. (Pubitemid 39628435)
36. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl. 2003a;26:76-83. (Pubitemid 36408236)
37. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 2007;92:3844-3853. (Pubitemid 47607632)
38. Zwart AD, Iranmanesh A, Veldhuis JD. Disparate serum free testosterone concentrations and degrees of hypothalamo-pituitary-luteinizing hormone suppression are achieved by continuous versus pulsatile intravenous androgen replacement in men: a clinical experimental model of ketoconazole-induced reversible hypoandrogenemia with controlled testosterone add-back. J Clin Endocrinol Metab. 1997;82:2062-2069. (Pubitemid 27287562)